{
    "id": 29096,
    "fullName": "CEP85L - PDGFRB",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CEP85L-PDGFRB results from the fusion of CEP85L and PDGFRB (PMID: 23186533). CEP85L-PDGFRB has been identified in myeloproliferative neoplasm (PMID: 23186533), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 12894,
                    "pubMedId": 23186533,
                    "title": "Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23186533"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 387119,
        "geneSymbol": "CEP85L",
        "terms": [
            "CEP85L",
            "bA57K17.2",
            "C6orf204",
            "NY-BR-15"
        ]
    },
    "variant": "CEP85L - PDGFRB",
    "createDate": "12/10/2018",
    "updateDate": "10/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5159,
                "geneSymbol": "PDGFRB",
                "terms": [
                    "PDGFRB",
                    "CD140B",
                    "IBGC4",
                    "IMF1",
                    "JTK12",
                    "KOGS",
                    "PDGFR",
                    "PDGFR-1",
                    "PDGFR1",
                    "PENTT"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15417,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib mesylate) treatment resulted in remission for greater than three years in a patient with a myeloproliferative neoplasm harboring a CEP85L-PDGFRB fusion (PMID: 23186533).",
            "molecularProfile": {
                "id": 31020,
                "profileName": "CEP85L - PDGFRB"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2226,
                "name": "myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12894,
                    "pubMedId": 23186533,
                    "title": "Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23186533"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31020,
            "profileName": "CEP85L - PDGFRB",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}